Thrombus - 2003

Recombinant VIIa – the universal haemostatic agent?
Eric J Watts
pp 1-4
Recombinant VIIa (rVIIa) is now established in the management of haemophilia with inhibitors. The fact that rVIIa given in adequate dose can lead to accelerated thrombin production bypassing Factor VIII has resulted in its use in other bleeding problem areas. rVIIa circulates but does not become biologically active until bound to tissue factor normally expressed on the surface of damaged cells or activated platelets; that is, its action is specific to the site of injury and it does not appear to cause systemic activation of coagulation. In addition to its use in haemophilia, it has been used in a variety of congenital bleeding disorders including qualitative and quantitative platelet defects.
BSH annual meeting, Glasgow 2003
Peter Rose
pp 2-2
The annual meeting of the British Society for Haematology (BSH) was recently held in Glasgow. Sessions for nurse specialists were included for the first time at the meeting.
The use of low molecular weight heparin in pregnancy
Rachel Hall and Denise O’Shaughnessy
pp 5-6
Venous thromboembolism (VTE) occurs in approximately 1 in 1,000 pregnancies, the risk being greatest in the six-week postpartum period. Pulmonary embolism (PE) occurs in around 1 in 3,000 pregnancies and approximately 1 in 100,000 pregnant women will die of PE. In real terms, ten pregnant women die of PE per annum in the UK, with the risk being spread equally between the antenatal and postpartum periods.
Mesenteric vein thrombosis
Denis J O’Keeffe
pp 7-7
Mesenteric vein thrombosis (MVT) is a rare disorder that was first noted in 1935 and continues to be associated with a high mortality. The mesenteric veins consist of the superior and inferior vein that drain blood from the vessels of the small bowel into the portal vein. Thrombosis of the mesenteric veins can lead to infarction of the small bowel, but fortunately it is rare. Two studies carried out in the 1960s indicated that MVT accounted for 0.01–0.06% of surgical admissions, while less than 20% of cases of mesenteric infarction are caused by MVT.
Nurse-led anticoagulant services: exercising accountability
Fiona Dobson
pp 9-11
The current government, in setting out its plans for modernising the NHS, emphasised the importance of enhanced multiprofessional working, working in new ways and across existing role boundaries. In addition the Chief Nursing Officer for England identified ten key roles for nurses considered central to improving service delivery.

Thrombus was previously supported by Bayer from 2014 to 2016, by Boehringer Ingelheim from 2009 to 2013, by sanofi-aventis from 2007 to 2008 and by Leo Pharma from 1998 to 2006.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Thrombus is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 1369-8117 (Print)  ISSN 2045-7855 (Online)